Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8100505,AUC,"AUC, Cmax, Tmax, and terminal phase t1/2, for 14C were consistently greater than vigabatrin (248.2 vs. 176.0 micrograms-hr/ml; 48.8 vs. 42.8 micrograms/ml; 0.7 vs. 0.6 hr; and 9.5 vs. 7.7 hr, respectively).",Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),[μgrams-hr] / [ml],248.2,10546,DB01080,Vigabatrin
,8100505,AUC,"AUC, Cmax, Tmax, and terminal phase t1/2, for 14C were consistently greater than vigabatrin (248.2 vs. 176.0 micrograms-hr/ml; 48.8 vs. 42.8 micrograms/ml; 0.7 vs. 0.6 hr; and 9.5 vs. 7.7 hr, respectively).",Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),[μgrams-hr] / [ml],176.0,10547,DB01080,Vigabatrin
,8100505,Cmax,"AUC, Cmax, Tmax, and terminal phase t1/2, for 14C were consistently greater than vigabatrin (248.2 vs. 176.0 micrograms-hr/ml; 48.8 vs. 42.8 micrograms/ml; 0.7 vs. 0.6 hr; and 9.5 vs. 7.7 hr, respectively).",Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),[μg] / [ml],48.8,10548,DB01080,Vigabatrin
,8100505,Cmax,"AUC, Cmax, Tmax, and terminal phase t1/2, for 14C were consistently greater than vigabatrin (248.2 vs. 176.0 micrograms-hr/ml; 48.8 vs. 42.8 micrograms/ml; 0.7 vs. 0.6 hr; and 9.5 vs. 7.7 hr, respectively).",Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),h,0.7,10549,DB01080,Vigabatrin
,8100505,Tmax,"AUC, Cmax, Tmax, and terminal phase t1/2, for 14C were consistently greater than vigabatrin (248.2 vs. 176.0 micrograms-hr/ml; 48.8 vs. 42.8 micrograms/ml; 0.7 vs. 0.6 hr; and 9.5 vs. 7.7 hr, respectively).",Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),[μg] / [ml],48.8,10550,DB01080,Vigabatrin
,8100505,Tmax,"AUC, Cmax, Tmax, and terminal phase t1/2, for 14C were consistently greater than vigabatrin (248.2 vs. 176.0 micrograms-hr/ml; 48.8 vs. 42.8 micrograms/ml; 0.7 vs. 0.6 hr; and 9.5 vs. 7.7 hr, respectively).",Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),h,0.7,10551,DB01080,Vigabatrin
,8100505,terminal phase t1/2,"AUC, Cmax, Tmax, and terminal phase t1/2, for 14C were consistently greater than vigabatrin (248.2 vs. 176.0 micrograms-hr/ml; 48.8 vs. 42.8 micrograms/ml; 0.7 vs. 0.6 hr; and 9.5 vs. 7.7 hr, respectively).",Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),h,0.6,10552,DB01080,Vigabatrin
,8100505,terminal phase t1/2,"AUC, Cmax, Tmax, and terminal phase t1/2, for 14C were consistently greater than vigabatrin (248.2 vs. 176.0 micrograms-hr/ml; 48.8 vs. 42.8 micrograms/ml; 0.7 vs. 0.6 hr; and 9.5 vs. 7.7 hr, respectively).",Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),h,9.5,10553,DB01080,Vigabatrin
,8100505,terminal phase t1/2,"AUC, Cmax, Tmax, and terminal phase t1/2, for 14C were consistently greater than vigabatrin (248.2 vs. 176.0 micrograms-hr/ml; 48.8 vs. 42.8 micrograms/ml; 0.7 vs. 0.6 hr; and 9.5 vs. 7.7 hr, respectively).",Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),h,7.7,10554,DB01080,Vigabatrin
,8100505,renal clearance,"Mean renal clearance, oral clearance, and volume of distribution for 14C was consistently lower than vigabatrin (1.20 vs. 1.45 ml/min/kg; 1.26 vs. 1.77 ml/min/kg; and 1.01 vs. 1.18 liters/kg, respectively).",Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),[ml] / [kg·min],1.20,10555,DB01080,Vigabatrin
,8100505,oral clearance,"Mean renal clearance, oral clearance, and volume of distribution for 14C was consistently lower than vigabatrin (1.20 vs. 1.45 ml/min/kg; 1.26 vs. 1.77 ml/min/kg; and 1.01 vs. 1.18 liters/kg, respectively).",Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),[ml] / [kg·min],1.45,10556,DB01080,Vigabatrin
,8100505,oral clearance,"Mean renal clearance, oral clearance, and volume of distribution for 14C was consistently lower than vigabatrin (1.20 vs. 1.45 ml/min/kg; 1.26 vs. 1.77 ml/min/kg; and 1.01 vs. 1.18 liters/kg, respectively).",Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),[ml] / [kg·min],1.26,10557,DB01080,Vigabatrin
,8100505,oral clearance,"Mean renal clearance, oral clearance, and volume of distribution for 14C was consistently lower than vigabatrin (1.20 vs. 1.45 ml/min/kg; 1.26 vs. 1.77 ml/min/kg; and 1.01 vs. 1.18 liters/kg, respectively).",Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),[ml] / [kg·min],1.77,10558,DB01080,Vigabatrin
,8100505,volume of distribution,"Mean renal clearance, oral clearance, and volume of distribution for 14C was consistently lower than vigabatrin (1.20 vs. 1.45 ml/min/kg; 1.26 vs. 1.77 ml/min/kg; and 1.01 vs. 1.18 liters/kg, respectively).",Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),[ml] / [kg·min],1.77,10559,DB01080,Vigabatrin
,8100505,volume of distribution,"Mean renal clearance, oral clearance, and volume of distribution for 14C was consistently lower than vigabatrin (1.20 vs. 1.45 ml/min/kg; 1.26 vs. 1.77 ml/min/kg; and 1.01 vs. 1.18 liters/kg, respectively).",Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),[l] / [kg],1.01,10560,DB01080,Vigabatrin
,8100505,volume of distribution,"Mean renal clearance, oral clearance, and volume of distribution for 14C was consistently lower than vigabatrin (1.20 vs. 1.45 ml/min/kg; 1.26 vs. 1.77 ml/min/kg; and 1.01 vs. 1.18 liters/kg, respectively).",Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),[l] / [kg],1.18,10561,DB01080,Vigabatrin
,8100505,percentage of recovery,The mean percentage of recovery of 14C in urine was higher than vigabatrin (95.4 vs. 82.0%).,Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),%,95.4,10562,DB01080,Vigabatrin
,8100505,percentage of recovery,The mean percentage of recovery of 14C in urine was higher than vigabatrin (95.4 vs. 82.0%).,Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),%,82.0,10563,DB01080,Vigabatrin
,8100505,percentage of recovery,The mean percentage of recovery of 14C in feces was 1.0%.,Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100505/),%,1.0,10564,DB01080,Vigabatrin
,18503564,elimination half-life,"During repeated dosing, steady state is reached within 2 days, consistent with its elimination half-life of 6-10 h.",Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18503564/),h,6-10,45117,DB01080,Vigabatrin
,2667604,Plasma elimination half-life,Plasma elimination half-life ranges between 5 and 7 h in normal volunteers.,Clinical pharmacology of vigabatrin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2667604/),h,5 and 7,51046,DB01080,Vigabatrin
,12576167,concentration at 1h (C(1h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],2.1,63306,DB01080,Vigabatrin
,12576167,concentration at 12h (C(12h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],0.8,63307,DB01080,Vigabatrin
,12576167,area under the curve from 0 to 12h (AUC(0-12h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],17.1,63308,DB01080,Vigabatrin
,12576167,half-life (t(1/2)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),h,8.1,63309,DB01080,Vigabatrin
,12576167,apparent oral clearance (CL/F),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),1/[mlmin],0.97,63310,DB01080,Vigabatrin
lower,9578192,milk: plasma concentration ratio,"The milk: plasma concentration ratio was lower than 1 at pre dose sampling in both cases, as well as 3 and 6 h post dose in one case.",Vigabatrin: placental transfer in vivo and excretion into breast milk of the enantiomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578192/),,1,79687,DB01080,Vigabatrin
,22234618,absolute bioavailability,Increasing the dose of vigabatrin 10-fold decreased the absolute bioavailability to 4.2%.,"Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22234618/),%,4.2,84796,DB01080,Vigabatrin
,22234618,K(m),Laevis oocytes had a K(m) of 5.2 ± 0.6 mM and was almost completely inhibited by tryptophan.,"Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22234618/),mM,5.2,84797,DB01080,Vigabatrin
,2206786,Cmax,2. The mean (+/- s.d.) values of maximum plasma concentration and area under the plasma concentration-time curve of the R(-) enantiomer were significantly higher than those of S(+) vigabatrin in both groups: R(-) Cmax: 21 +/- 6.6 (I)-41.3 +/- 13.9 (II) vs S(+) Cmax: 13.9 +/- 4.5 (I)-23.8 +/- 12.2 (II) mg l-1; R(-) AUC: 106 +/- 28.5 (I)-147 +/- 34 (II) vs S(+) AUC: 90.9 +/- 27.9 (I)-117 +/- 26 (II) mg l-1 h.,Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206786/),,21,94174,DB01080,Vigabatrin
,2206786,Cmax,2. The mean (+/- s.d.) values of maximum plasma concentration and area under the plasma concentration-time curve of the R(-) enantiomer were significantly higher than those of S(+) vigabatrin in both groups: R(-) Cmax: 21 +/- 6.6 (I)-41.3 +/- 13.9 (II) vs S(+) Cmax: 13.9 +/- 4.5 (I)-23.8 +/- 12.2 (II) mg l-1; R(-) AUC: 106 +/- 28.5 (I)-147 +/- 34 (II) vs S(+) AUC: 90.9 +/- 27.9 (I)-117 +/- 26 (II) mg l-1 h.,Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206786/),,41.3,94175,DB01080,Vigabatrin
,2206786,Cmax,2. The mean (+/- s.d.) values of maximum plasma concentration and area under the plasma concentration-time curve of the R(-) enantiomer were significantly higher than those of S(+) vigabatrin in both groups: R(-) Cmax: 21 +/- 6.6 (I)-41.3 +/- 13.9 (II) vs S(+) Cmax: 13.9 +/- 4.5 (I)-23.8 +/- 12.2 (II) mg l-1; R(-) AUC: 106 +/- 28.5 (I)-147 +/- 34 (II) vs S(+) AUC: 90.9 +/- 27.9 (I)-117 +/- 26 (II) mg l-1 h.,Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206786/),[mg] / [l],13.9,94176,DB01080,Vigabatrin
,2206786,Cmax,2. The mean (+/- s.d.) values of maximum plasma concentration and area under the plasma concentration-time curve of the R(-) enantiomer were significantly higher than those of S(+) vigabatrin in both groups: R(-) Cmax: 21 +/- 6.6 (I)-41.3 +/- 13.9 (II) vs S(+) Cmax: 13.9 +/- 4.5 (I)-23.8 +/- 12.2 (II) mg l-1; R(-) AUC: 106 +/- 28.5 (I)-147 +/- 34 (II) vs S(+) AUC: 90.9 +/- 27.9 (I)-117 +/- 26 (II) mg l-1 h.,Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206786/),[mg] / [l],23.8,94177,DB01080,Vigabatrin
,2206786,AUC,2. The mean (+/- s.d.) values of maximum plasma concentration and area under the plasma concentration-time curve of the R(-) enantiomer were significantly higher than those of S(+) vigabatrin in both groups: R(-) Cmax: 21 +/- 6.6 (I)-41.3 +/- 13.9 (II) vs S(+) Cmax: 13.9 +/- 4.5 (I)-23.8 +/- 12.2 (II) mg l-1; R(-) AUC: 106 +/- 28.5 (I)-147 +/- 34 (II) vs S(+) AUC: 90.9 +/- 27.9 (I)-117 +/- 26 (II) mg l-1 h.,Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206786/),,106,94178,DB01080,Vigabatrin
,2206786,AUC,2. The mean (+/- s.d.) values of maximum plasma concentration and area under the plasma concentration-time curve of the R(-) enantiomer were significantly higher than those of S(+) vigabatrin in both groups: R(-) Cmax: 21 +/- 6.6 (I)-41.3 +/- 13.9 (II) vs S(+) Cmax: 13.9 +/- 4.5 (I)-23.8 +/- 12.2 (II) mg l-1; R(-) AUC: 106 +/- 28.5 (I)-147 +/- 34 (II) vs S(+) AUC: 90.9 +/- 27.9 (I)-117 +/- 26 (II) mg l-1 h.,Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206786/),[h·mg] / [l],147,94179,DB01080,Vigabatrin
,2206786,AUC,2. The mean (+/- s.d.) values of maximum plasma concentration and area under the plasma concentration-time curve of the R(-) enantiomer were significantly higher than those of S(+) vigabatrin in both groups: R(-) Cmax: 21 +/- 6.6 (I)-41.3 +/- 13.9 (II) vs S(+) Cmax: 13.9 +/- 4.5 (I)-23.8 +/- 12.2 (II) mg l-1; R(-) AUC: 106 +/- 28.5 (I)-147 +/- 34 (II) vs S(+) AUC: 90.9 +/- 27.9 (I)-117 +/- 26 (II) mg l-1 h.,Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206786/),[h·mg] / [l],90.9,94180,DB01080,Vigabatrin
,2206786,AUC,2. The mean (+/- s.d.) values of maximum plasma concentration and area under the plasma concentration-time curve of the R(-) enantiomer were significantly higher than those of S(+) vigabatrin in both groups: R(-) Cmax: 21 +/- 6.6 (I)-41.3 +/- 13.9 (II) vs S(+) Cmax: 13.9 +/- 4.5 (I)-23.8 +/- 12.2 (II) mg l-1; R(-) AUC: 106 +/- 28.5 (I)-147 +/- 34 (II) vs S(+) AUC: 90.9 +/- 27.9 (I)-117 +/- 26 (II) mg l-1 h.,Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2206786/),[h·mg] / [l],117,94181,DB01080,Vigabatrin
,14506315,ED(30),Vigabatrin inhibited the clonic pentetrazole-induced seizures and ED(30) of the drug was 879 mg/kg.,"Influence of vigabatrin, a novel antiepileptic drug, on the anticonvulsant activity of conventional antiepileptics in pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506315/),[mg] / [kg],879,115573,DB01080,Vigabatrin
,14506315,ED(30),"Vigabatrin (at the subthreshold dose of 250 mg/kg) potentiated the protective activity of ethosuximide, reducing its ED(30) from 142 to 95 mg/kg against clonic seizures induced by pentetrazole, but simultaneously elevated its plasma level.","Influence of vigabatrin, a novel antiepileptic drug, on the anticonvulsant activity of conventional antiepileptics in pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506315/),[mg] / [kg],142,115574,DB01080,Vigabatrin
,14506315,ED(30),"Vigabatrin (at the subthreshold dose of 250 mg/kg) potentiated the protective activity of ethosuximide, reducing its ED(30) from 142 to 95 mg/kg against clonic seizures induced by pentetrazole, but simultaneously elevated its plasma level.","Influence of vigabatrin, a novel antiepileptic drug, on the anticonvulsant activity of conventional antiepileptics in pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506315/),[mg] / [kg],95,115575,DB01080,Vigabatrin
,25562534,Michaelis constant,"Using a Michaelis constant of 32.8mM, the model estimated a maximal oral absorption rate (Vmax) of 64.6mmol/min and dose-dependent bioavailability with a maximum of 60.9%.",Is oral absorption of vigabatrin carrier-mediated? ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25562534/),mM,32.8,128187,DB01080,Vigabatrin
,25562534,maximal oral absorption rate (Vmax),"Using a Michaelis constant of 32.8mM, the model estimated a maximal oral absorption rate (Vmax) of 64.6mmol/min and dose-dependent bioavailability with a maximum of 60.9%.",Is oral absorption of vigabatrin carrier-mediated? ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25562534/),[mM] / [min],64.6,128188,DB01080,Vigabatrin
,25562534,bioavailability,"Using a Michaelis constant of 32.8mM, the model estimated a maximal oral absorption rate (Vmax) of 64.6mmol/min and dose-dependent bioavailability with a maximum of 60.9%.",Is oral absorption of vigabatrin carrier-mediated? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25562534/),%,60.9,128189,DB01080,Vigabatrin
,25562534,Bioavailability,"Bioavailability was 58.5-60.8% at 0.3-30mg/kg doses, but decreased to 46.8% at 300mg/kg.",Is oral absorption of vigabatrin carrier-mediated? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25562534/),%,58.5-60.8,128190,DB01080,Vigabatrin
,25562534,Bioavailability,"Bioavailability was 58.5-60.8% at 0.3-30mg/kg doses, but decreased to 46.8% at 300mg/kg.",Is oral absorption of vigabatrin carrier-mediated? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25562534/),%,46.8,128191,DB01080,Vigabatrin
,9186253,half-life,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),h,15.5,128388,DB01080,Vigabatrin
,9186253,half-life,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),h,14.1,128389,DB01080,Vigabatrin
,9186253,excretion,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[nM] / [d],488,128390,DB01080,Vigabatrin
,9186253,excretion,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[nM] / [d],470,128391,DB01080,Vigabatrin
,9186253,concentration ratio,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),,6.8,128392,DB01080,Vigabatrin
,9186253,concentration ratio,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),,6.1,128393,DB01080,Vigabatrin
,9186253,half-life,"No difference in pharmacokinetic parameters between VGB and placebo sessions were found for ethinyl estradiol (half-life, 12.5 +/- 3.2 vs.","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),,12.5,128394,DB01080,Vigabatrin
,9186253,AUC,"13.9 +/- 3.2 h; AUC, 874 +/- 301 vs. 939 +/- 272 ng/ L/h) and levonorgestrel (half-life, 17.7 +/- 5.2 vs.","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[ng] / [h·l],874,128395,DB01080,Vigabatrin
,9186253,AUC,"13.9 +/- 3.2 h; AUC, 874 +/- 301 vs. 939 +/- 272 ng/ L/h) and levonorgestrel (half-life, 17.7 +/- 5.2 vs.","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[ng] / [h·l],939,128396,DB01080,Vigabatrin
,9186253,half-life,"13.9 +/- 3.2 h; AUC, 874 +/- 301 vs. 939 +/- 272 ng/ L/h) and levonorgestrel (half-life, 17.7 +/- 5.2 vs.","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),,17.7,128397,DB01080,Vigabatrin
,9186253,AUC,"23.1 +/- 9.8 h; AUC, 27.5 +/- 9.6 vs. 30.0 +/- 12.0 micrograms/L/h).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[μg] / [h·l],27.5,128398,DB01080,Vigabatrin
,9186253,AUC,"23.1 +/- 9.8 h; AUC, 27.5 +/- 9.6 vs. 30.0 +/- 12.0 micrograms/L/h).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[μg] / [h·l],30.0,128399,DB01080,Vigabatrin
,1940127,plasma half-life,"It is cleared rapidly by renal elimination (giving a plasma half-life of approximately 7 to 9 hours), and therefore the effect of the drug long outlasts its presence in the body.",Pharmacology and clinical pharmacology of vigabatrin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940127/),h,7 to 9,136060,DB01080,Vigabatrin
,2757905,terminal half-life,3. The plasma concentration vs time profile followed a bi-exponential decline with a terminal half-life of 6.8 h and a relative bioavailability of 92% +/- 11%.,Effect of food on the absorption of vigabatrin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2757905/),h,6.8,148113,DB01080,Vigabatrin
,2757905,relative bioavailability,3. The plasma concentration vs time profile followed a bi-exponential decline with a terminal half-life of 6.8 h and a relative bioavailability of 92% +/- 11%.,Effect of food on the absorption of vigabatrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2757905/),%,92,148114,DB01080,Vigabatrin
,30192381,apparent clearance,"Mean population estimates (percentage interindividual variability) for the apparent clearance, apparent distribution volume, and absorption duration were 2.36 L/h (24.5%), 17 L (38%), and 0.682 hours, respectively.",Proposition of a Minimal Effective Dose of Vigabatrin for the Treatment of Infantile Spasms Using Pediatric and Adult Pharmacokinetic Data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30192381/),[l] / [h],2.36,178576,DB01080,Vigabatrin
,30192381,apparent distribution volume,"Mean population estimates (percentage interindividual variability) for the apparent clearance, apparent distribution volume, and absorption duration were 2.36 L/h (24.5%), 17 L (38%), and 0.682 hours, respectively.",Proposition of a Minimal Effective Dose of Vigabatrin for the Treatment of Infantile Spasms Using Pediatric and Adult Pharmacokinetic Data. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30192381/),l,17,178577,DB01080,Vigabatrin
,30192381,absorption duration,"Mean population estimates (percentage interindividual variability) for the apparent clearance, apparent distribution volume, and absorption duration were 2.36 L/h (24.5%), 17 L (38%), and 0.682 hours, respectively.",Proposition of a Minimal Effective Dose of Vigabatrin for the Treatment of Infantile Spasms Using Pediatric and Adult Pharmacokinetic Data. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30192381/),h,0.682,178578,DB01080,Vigabatrin
,1395360,apparent volume of distribution,"The apparent volume of distribution of [R,S]-vigabatrin was approximately 0.8 L/kg.",Vigabatrin. Clinical pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1395360/),[l] / [kg],0.8,189507,DB01080,Vigabatrin
,1395360,half-life,"The half-life of [R,S]-vigabatrin was between 5.3 and 7.4h, the half-life of the enantiomers were 7.5 and 8.1h for the S(+) and the R(-) forms, respectively.",Vigabatrin. Clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1395360/),h,5.3 and 7.4,189508,DB01080,Vigabatrin
,1395360,half-life,"The half-life of [R,S]-vigabatrin was between 5.3 and 7.4h, the half-life of the enantiomers were 7.5 and 8.1h for the S(+) and the R(-) forms, respectively.",Vigabatrin. Clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1395360/),h,7.5,189509,DB01080,Vigabatrin
,1395360,half-life,"The half-life of [R,S]-vigabatrin was between 5.3 and 7.4h, the half-life of the enantiomers were 7.5 and 8.1h for the S(+) and the R(-) forms, respectively.",Vigabatrin. Clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1395360/),h,8.1,189510,DB01080,Vigabatrin
,1395360,urinary recovery,"The major route of elimination was renal excretion; urinary recovery of the [R,S]-vigabatrin was close to 70%.",Vigabatrin. Clinical pharmacokinetics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1395360/),%,70,189511,DB01080,Vigabatrin
,1395360,half-life,"In adults with epilepsy, the half-life of the [R,S]-vigabatrin ranged from 4.2 and 5.6h, similar to that measured in healthy adults.",Vigabatrin. Clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1395360/),h,4.2,189512,DB01080,Vigabatrin
,1395360,half-life,"In adults with epilepsy, the half-life of the [R,S]-vigabatrin ranged from 4.2 and 5.6h, similar to that measured in healthy adults.",Vigabatrin. Clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1395360/),h,5.6,189513,DB01080,Vigabatrin
,17118677,time to maximum concentration (Tmax),"Vigabatrin concentrations in blood and CSF rose linearly and dose-dependently and the time to maximum concentration (Tmax) was 0.4 and 1.0h, respectively.",The pharmacokinetics of vigabatrin in rat blood and cerebrospinal fluid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17118677/),h,0.4,202913,DB01080,Vigabatrin
,17118677,time to maximum concentration (Tmax),"Vigabatrin concentrations in blood and CSF rose linearly and dose-dependently and the time to maximum concentration (Tmax) was 0.4 and 1.0h, respectively.",The pharmacokinetics of vigabatrin in rat blood and cerebrospinal fluid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17118677/),h,1.0,202914,DB01080,Vigabatrin
,17118677,t1/2,"Vigabatrin is not protein bound in serum and its elimination from serum (mean t1/2 values, 1.1-1.4 h) is rapid and dose-independent.",The pharmacokinetics of vigabatrin in rat blood and cerebrospinal fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17118677/),h,1.1-1.4,202915,DB01080,Vigabatrin
,17118677,t1/2,"The efflux of vigabatrin from CSF was significantly slower than that seen for serum (mean t1/2 values, 2.2-3.3h).",The pharmacokinetics of vigabatrin in rat blood and cerebrospinal fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17118677/),h,2.2-3.3,202916,DB01080,Vigabatrin
,15058588,analytical,The method is precise (relative standard deviation (R.S.D.) <9.13%) and accurate (relative mean error (RME) <-8.75%); analytical recoveries were 81.07% for plasma and 83.05% for urine.,Determination of vigabatrin in human plasma and urine by high-performance liquid chromatography with UV-Vis detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15058588/),%,81.07,205637,DB01080,Vigabatrin
,15058588,recoveries,The method is precise (relative standard deviation (R.S.D.) <9.13%) and accurate (relative mean error (RME) <-8.75%); analytical recoveries were 81.07% for plasma and 83.05% for urine.,Determination of vigabatrin in human plasma and urine by high-performance liquid chromatography with UV-Vis detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15058588/),%,81.07,205638,DB01080,Vigabatrin
,15058588,recoveries,The method is precise (relative standard deviation (R.S.D.) <9.13%) and accurate (relative mean error (RME) <-8.75%); analytical recoveries were 81.07% for plasma and 83.05% for urine.,Determination of vigabatrin in human plasma and urine by high-performance liquid chromatography with UV-Vis detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15058588/),%,83.05,205639,DB01080,Vigabatrin
,24802902,maximum concentration of VGB (Cmax ),"After the first VGB dose, the maximum concentration of VGB (Cmax ) was 31.7 (26.9-42.6) μmol l(-1) (median and interquartile range for eight patients) in plasma and 2.41 (2.03-5.94) μmol l(-1) in brain microdialysates (nine patients, 11 catheters), without significant plasma-brain correlation.",Monitoring vigabatrin in head injury patients by cerebral microdialysis: obtaining pharmacokinetic measurements in a neurocritical care setting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24802902/),[μM] / [l],31.7,225442,DB01080,Vigabatrin
,24802902,maximum concentration of VGB (Cmax ),"After the first VGB dose, the maximum concentration of VGB (Cmax ) was 31.7 (26.9-42.6) μmol l(-1) (median and interquartile range for eight patients) in plasma and 2.41 (2.03-5.94) μmol l(-1) in brain microdialysates (nine patients, 11 catheters), without significant plasma-brain correlation.",Monitoring vigabatrin in head injury patients by cerebral microdialysis: obtaining pharmacokinetic measurements in a neurocritical care setting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24802902/),[μM] / [l],2.41,225443,DB01080,Vigabatrin
,24802902,Cmax,"After three doses, median Cmax in microdialysates increased to 5.22 (4.24-7.14) μmol l(-1) (eight patients, 10 catheters).",Monitoring vigabatrin in head injury patients by cerebral microdialysis: obtaining pharmacokinetic measurements in a neurocritical care setting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24802902/),[μM] / [l],5.22,225444,DB01080,Vigabatrin
,8902928,terminal elimination half-life,The terminal elimination half-life in this patient was 41 hours during the period of severe renal failure (creatinine clearance < 5 ml/min).,Vigabatrin dosing during haemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902928/),h,41,229013,DB01080,Vigabatrin
,9278207,apparent oral clearance,"Before dialysis, the maximum and minimun plasma concentrations of vigabatrin at steady-state were lower for the S(+) than for the R(-) enantiomer, while the apparent oral clearance was higher for the S(+) than for the R(-) enantiomer (2.97 vs 0.48 l h(-1)).",Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278207/),[l] / [h],2.97,230786,DB01080,Vigabatrin
,9278207,apparent oral clearance,"Before dialysis, the maximum and minimun plasma concentrations of vigabatrin at steady-state were lower for the S(+) than for the R(-) enantiomer, while the apparent oral clearance was higher for the S(+) than for the R(-) enantiomer (2.97 vs 0.48 l h(-1)).",Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278207/),[l] / [h],0.48,230787,DB01080,Vigabatrin
,9278207,clearance,"In addition, the haemodialysis clearance was similar for the two enantiomers (4.96 vs 5.15 l h(-1)).",Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278207/),[l] / [h],4.96,230788,DB01080,Vigabatrin
,9278207,clearance,"In addition, the haemodialysis clearance was similar for the two enantiomers (4.96 vs 5.15 l h(-1)).",Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278207/),[l] / [h],5.15,230789,DB01080,Vigabatrin
,17481975,flow-rate,"Separation is achieved on a reversed-phase cellulose-based chiral column (Chiralcel-ODR, 250 mm x 4.6 mm i.d.) using 0.05 M potassium hexafluorophosphate (pH 4.5)/acetonitrile/ethanol (50:40:10 vol/vol/vol) as mobile phase at a flow-rate of 0.9 mL/min.",Stereoselective determination of vigabatrin enantiomers in human plasma by high performance liquid chromatography using UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17481975/),[ml] / [min],0.9,232447,DB01080,Vigabatrin
,8827398,half-life,"When used as a monotherapy, topiramate is eliminated primarily in the urine in an unchanged form with a half-life of 20 to 30 hours; elimination is faster in patients receiving concurrent medication with enzyme-inducing anticonvulsants, in whom the extent of biotransformation becomes more prominent.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,20 to 30,232847,DB01080,Vigabatrin
,8827398,half-life,"It is rapidly absorbed, 50% bound to plasma proteins and is eliminated predominantly by biotransformation; zonisamide has a half-life of 50 to 70 hours in monotherapy patients, or 25 to 35 hours in patients comedicated with enzyme-inducing anticonvulsants.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,50 to 70,232848,DB01080,Vigabatrin
,8827398,half-life,"It is rapidly absorbed, 50% bound to plasma proteins and is eliminated predominantly by biotransformation; zonisamide has a half-life of 50 to 70 hours in monotherapy patients, or 25 to 35 hours in patients comedicated with enzyme-inducing anticonvulsants.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,25 to 35,232849,DB01080,Vigabatrin
,8827398,half-life,"It is highly (96%) bound to plasma proteins and it is eliminated primarily by cytochrome P450 3A-mediated oxidation, with a half-life of about 7 hours in healthy volunteers.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,7,232850,DB01080,Vigabatrin
,8971436,Cmax,"The mean values of Cmax and AUC of the S(+) enantiomer were significantly lower (Cmax: 14.0 +/- 4.3 mg l-1; AUC: 143 +/- 44 mg l-1 h) than those of the R(-) enantiomer (Cmax: 34.1 +/- 9.5 mg l-1; AUC: 231 +/- 88 mg l-1 h), whereas no significant difference in the time to reach Cmax (S(+): 2.1 +/- 1.1 h; R(-): 2.2 +/- 1 h) was observed between the two enantiomers.",Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971436/),[mg] / [l],14.0,242730,DB01080,Vigabatrin
,8971436,AUC,"The mean values of Cmax and AUC of the S(+) enantiomer were significantly lower (Cmax: 14.0 +/- 4.3 mg l-1; AUC: 143 +/- 44 mg l-1 h) than those of the R(-) enantiomer (Cmax: 34.1 +/- 9.5 mg l-1; AUC: 231 +/- 88 mg l-1 h), whereas no significant difference in the time to reach Cmax (S(+): 2.1 +/- 1.1 h; R(-): 2.2 +/- 1 h) was observed between the two enantiomers.",Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971436/),[h·mg] / [l],143,242731,DB01080,Vigabatrin
,8971436,Cmax,"The mean values of Cmax and AUC of the S(+) enantiomer were significantly lower (Cmax: 14.0 +/- 4.3 mg l-1; AUC: 143 +/- 44 mg l-1 h) than those of the R(-) enantiomer (Cmax: 34.1 +/- 9.5 mg l-1; AUC: 231 +/- 88 mg l-1 h), whereas no significant difference in the time to reach Cmax (S(+): 2.1 +/- 1.1 h; R(-): 2.2 +/- 1 h) was observed between the two enantiomers.",Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971436/),[mg] / [l],34.1,242732,DB01080,Vigabatrin
,8971436,AUC,"The mean values of Cmax and AUC of the S(+) enantiomer were significantly lower (Cmax: 14.0 +/- 4.3 mg l-1; AUC: 143 +/- 44 mg l-1 h) than those of the R(-) enantiomer (Cmax: 34.1 +/- 9.5 mg l-1; AUC: 231 +/- 88 mg l-1 h), whereas no significant difference in the time to reach Cmax (S(+): 2.1 +/- 1.1 h; R(-): 2.2 +/- 1 h) was observed between the two enantiomers.",Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971436/),[h·mg] / [l],231,242733,DB01080,Vigabatrin
,8971436,time to reach Cmax,"The mean values of Cmax and AUC of the S(+) enantiomer were significantly lower (Cmax: 14.0 +/- 4.3 mg l-1; AUC: 143 +/- 44 mg l-1 h) than those of the R(-) enantiomer (Cmax: 34.1 +/- 9.5 mg l-1; AUC: 231 +/- 88 mg l-1 h), whereas no significant difference in the time to reach Cmax (S(+): 2.1 +/- 1.1 h; R(-): 2.2 +/- 1 h) was observed between the two enantiomers.",Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971436/),h,2.1,242734,DB01080,Vigabatrin
,8971436,time to reach Cmax,"The mean values of Cmax and AUC of the S(+) enantiomer were significantly lower (Cmax: 14.0 +/- 4.3 mg l-1; AUC: 143 +/- 44 mg l-1 h) than those of the R(-) enantiomer (Cmax: 34.1 +/- 9.5 mg l-1; AUC: 231 +/- 88 mg l-1 h), whereas no significant difference in the time to reach Cmax (S(+): 2.1 +/- 1.1 h; R(-): 2.2 +/- 1 h) was observed between the two enantiomers.",Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971436/),h,2.2,242735,DB01080,Vigabatrin
,3769388,terminal t1/2,The mean terminal t1/2 ranged from 6 to 8 hours for both enantiomers.,Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3769388/),h,6 to 8,247439,DB01080,Vigabatrin
,3769388,urinary recovery,Mean urinary recovery of the S(+)-enantiomer was 49% after both doses and was 65% for the R(-)-enantiomer.,Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3769388/),%,49,247440,DB01080,Vigabatrin
,3769388,urinary recovery,Mean urinary recovery of the S(+)-enantiomer was 49% after both doses and was 65% for the R(-)-enantiomer.,Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3769388/),%,65,247441,DB01080,Vigabatrin
,33385945,partition coefficient,"In brain, eye and plasma, the ((S)-(+)/(R)-(-)) ratio varied from 0.73 to 1.29 and 13.3 in retina, accompanied by a partition coefficient (tissue/plasma, ((S)-(+);(R)-(-))) of 5.8;0.34, 0.63;0.49, and 0.51;0.34 in retina, eye and brain, respectively.",Preferential accumulation of the active S-(+) isomer in murine retina highlights novel mechanisms of vigabatrin-associated retinal toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33385945/),,5.8,257507,DB01080,Vigabatrin
,33385945,partition coefficient,"In brain, eye and plasma, the ((S)-(+)/(R)-(-)) ratio varied from 0.73 to 1.29 and 13.3 in retina, accompanied by a partition coefficient (tissue/plasma, ((S)-(+);(R)-(-))) of 5.8;0.34, 0.63;0.49, and 0.51;0.34 in retina, eye and brain, respectively.",Preferential accumulation of the active S-(+) isomer in murine retina highlights novel mechanisms of vigabatrin-associated retinal toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33385945/),,0.34,257508,DB01080,Vigabatrin
,33385945,partition coefficient,"In brain, eye and plasma, the ((S)-(+)/(R)-(-)) ratio varied from 0.73 to 1.29 and 13.3 in retina, accompanied by a partition coefficient (tissue/plasma, ((S)-(+);(R)-(-))) of 5.8;0.34, 0.63;0.49, and 0.51;0.34 in retina, eye and brain, respectively.",Preferential accumulation of the active S-(+) isomer in murine retina highlights novel mechanisms of vigabatrin-associated retinal toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33385945/),,0.63,257509,DB01080,Vigabatrin
,33385945,partition coefficient,"In brain, eye and plasma, the ((S)-(+)/(R)-(-)) ratio varied from 0.73 to 1.29 and 13.3 in retina, accompanied by a partition coefficient (tissue/plasma, ((S)-(+);(R)-(-))) of 5.8;0.34, 0.63;0.49, and 0.51;0.34 in retina, eye and brain, respectively.",Preferential accumulation of the active S-(+) isomer in murine retina highlights novel mechanisms of vigabatrin-associated retinal toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33385945/),,0.49,257510,DB01080,Vigabatrin
,33385945,partition coefficient,"In brain, eye and plasma, the ((S)-(+)/(R)-(-)) ratio varied from 0.73 to 1.29 and 13.3 in retina, accompanied by a partition coefficient (tissue/plasma, ((S)-(+);(R)-(-))) of 5.8;0.34, 0.63;0.49, and 0.51;0.34 in retina, eye and brain, respectively.",Preferential accumulation of the active S-(+) isomer in murine retina highlights novel mechanisms of vigabatrin-associated retinal toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33385945/),,0.51,257511,DB01080,Vigabatrin
,25172554,k tr,"For the study of children with IS, inter-occasion variability was estimated for k tr (58.1 %) and relative bioavailability (F) (26.9 %).",Population pharmacokinetics analysis of vigabatrin in adults and children with epilepsy and children with infantile spasms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25172554/),%,58.1,258094,DB01080,Vigabatrin
,25172554,relative bioavailability (F),"For the study of children with IS, inter-occasion variability was estimated for k tr (58.1 %) and relative bioavailability (F) (26.9 %).",Population pharmacokinetics analysis of vigabatrin in adults and children with epilepsy and children with infantile spasms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25172554/),%,26.9,258095,DB01080,Vigabatrin
,12472982,trough concentrations,"Mean trough concentrations were 7.9 +/- 1.4 microg/mL with carbamazepine alone, and 6.5 +/- 2.0 microg/mL with carbamazepine-vigabatrin association (P < 0.03).",Effect of vigabatrin on the pharmacokinetics of carbamazepine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12472982/),[μg] / [ml],7.9,259211,DB01080,Vigabatrin
,12472982,trough concentrations,"Mean trough concentrations were 7.9 +/- 1.4 microg/mL with carbamazepine alone, and 6.5 +/- 2.0 microg/mL with carbamazepine-vigabatrin association (P < 0.03).",Effect of vigabatrin on the pharmacokinetics of carbamazepine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12472982/),[μg] / [ml],6.5,259212,DB01080,Vigabatrin
,12472982,level/dose ratio (L/D),The mean values of pharmacokinetic parameters were: level/dose ratio (L/D) = 0.59 +/- 0.20 vs.,Effect of vigabatrin on the pharmacokinetics of carbamazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12472982/),,0.59,259213,DB01080,Vigabatrin
,12472982,plasma clearance (Cl),"0.45 +/- 0.15 (P < 0.05) and plasma clearance (Cl) = 78.5 +/- 25.8 vs. 105.8 +/- 38.9 mL/h/kg (P < 0.05), with carbamazepine alone and carbamazepine-vigabatrin combination, respectively.",Effect of vigabatrin on the pharmacokinetics of carbamazepine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12472982/),[ml] / [h·kg],78.5,259214,DB01080,Vigabatrin
,12472982,plasma clearance (Cl),"0.45 +/- 0.15 (P < 0.05) and plasma clearance (Cl) = 78.5 +/- 25.8 vs. 105.8 +/- 38.9 mL/h/kg (P < 0.05), with carbamazepine alone and carbamazepine-vigabatrin combination, respectively.",Effect of vigabatrin on the pharmacokinetics of carbamazepine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12472982/),[ml] / [h·kg],105.8,259215,DB01080,Vigabatrin
,12915337,half-life,"Although its half-life is relatively short (6 to 8 hours), its duration of action is longer than anticipated from its pharmacokinetics in plasma, and a twice-daily dosing regimen is adequate to produce the desired response.",The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915337/),h,6 to 8,271378,DB01080,Vigabatrin
